NovaBridge Biosciences Capital Expenditures (CapEx) Growth & History (NBP)
NovaBridge Biosciences's capital expenditures (capex) was $7,000 for fiscal 2025.
View full NovaBridge Biosciences company overviewNovaBridge Biosciences annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7,000 | −$41,000 | −85.42% |
| 2024 | 2024-12-31 | $48,000 | −$116,000 | −70.73% |
| 2023 | 2023-12-31 | $164,000 | −$1.9M | −92.16% |
| 2022 | 2022-12-31 | $2.1M | −$2.6M | −55.48% |
| 2021 | 2021-12-31 | $4.7M | $3.5M | +282.80% |
| 2020 | 2020-12-31 | $1.2M | −$531,000 | −30.20% |
| 2019 | 2019-12-31 | $1.8M | — | — |
NovaBridge Biosciences quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $0 | −$1,000 | — |
| Q4 2024 | 2024-12-31 | $38,000 | — | — |
| Q3 2024 | 2024-09-30 | $1,000 | — | — |
NovaBridge Biosciences capital expenditures (capex) trends
Over the last five fiscal years, NovaBridge Biosciences's capital expenditures (capex) decreased from $1.2M to $7,000, a change of −$1.2M. The latest reported quarter, Q3 2025, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovaBridge Biosciences source filings ↗